.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The evidence surrounding early antibiotic treatment in sepsis consistently supports prompt therapy for patients with suspected life-threatening infection, but also highlights the harms of unnecessary broad-spectrum exposure. Observational studies have linked delays in effective antibiotics with worse outcomes, while modern stewardship frameworks emphasize obtaining cultures rapidly, assessing the likelihood of bacterial infection and narrowing therapy when results become available. For general physicians, the challenge is operational: recognize sepsis early, establish source control and start appropriate empiric therapy without allowing “broad spectrum” to become synonymous with “better.” Local resistance data, prior microbiology, recent antibiotic exposure and healthcare-associated risk all matter. Reassessment at 24–72 hours is essential. At that point, de-escalation, discontinuation or narrowing should be considered when the clinical course and diagnostics support it. This approach addresses both the immediate patient's survival and the longer-term public-health threat of antimicrobial resistance, making it particularly relevant to APICON's infectious-disease and practical-medicine emphasis.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The evidence surrounding early antibiotic treatment in sepsis consistently supports prompt therapy for patients with suspected life-threatening infection, but also highlights the harms of unnecessary broad-spectrum exposure. Observational studies have linked delays in effective antibiotics with worse outcomes, while modern stewardship frameworks emphasize obtaining cultures rapidly, assessing the likelihood of bacterial infection and narrowing therapy when results become available. For general physicians, the challenge is operational: recognize sepsis early, establish source control and start appropriate empiric therapy without allowing “broad spectrum” to become synonymous with “better.” Local resistance data, prior microbiology, recent antibiotic exposure and healthcare-associated risk all matter. Reassessment at 24–72 hours is essential. At that point, de-escalation, discontinuation or narrowing should be considered when the clinical course and diagnostics support it. This approach addresses both the immediate patient's survival and the longer-term public-health threat of antimicrobial resistance, making it particularly relevant to APICON's infectious-disease and practical-medicine emphasis.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
